University of Pennsylvania Cancer Center
Last Modified: May 18, 1999
Last year a major study of 13,000 women demonstrated that tamoxifen can significantly reduce the risk of developing breast cancer in some women. In October 1998, the federal Food and Drug Administration (FDA) approved the drug for use in women at increase risk of developing the disease. Now, after further analysis of the data, researchers have found that the drug also benefits women who have benign conditions that may or may not develop into invasive breast cancer.
Dr. Donald Wickerham and his colleagues at the National Surgical Adjuvant Breast and Bowel Project (NSABP) studied a sub-set of 2,019 women in the original Breast Cancer Prevention Trial, which enrolled more than 13,000 participants. They specifically looked at women whose biopsied breast tissue showed either lobular carcinoma in-situ (LCIS) or atypical hyperplasia (AH). These relatively rare conditions are considered indicators that a woman is at risk or developing the disease.
Wickerham found that women with LCIS or AH who took tamoxifen significantly reduced their chance of developing invasive breast cancer compared with a control group that took a placebo, or dummy pill. In the study, 8 women with LCIS in the tamoxifen group developed cancer, compared to 18 women who took a placebo a 66 percent reduction. Results were even more dramatic for women diagnosed with AH. Only 3 women with AH who took tamoxifen developed invasive breast cancer compared to 23 women in the control group an 86 percent reduction in invasive breast cancer cases.
Jun 5, 2013 - For women with estrogen receptor (ER) positive or ER untested invasive breast cancer, continuing tamoxifen for 10 years is associated with significant reductions in recurrence and breast cancer mortality, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.
Sep 20, 2012
Mar 24, 2011